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Introduction: Bacteremia remains a major cause of life-threatening complications in
patients receiving anticancer chemotherapy. The spectrum and susceptibility profiles of
causative microorganisms differ with time and place. Data from Lebanon are scarce. We
aim at evaluating the epidemiology of bacteremia in cancer patients in a university hospital
in Lebanon, emphasizing antibiotic resistance and risk factors of multi-drug resistant
organism (MDRO)-associated bacteremia.
Materials and Methods: This is a retrospective study of 75 episodes of bacteremia
occurring in febrile neutropenic patients admitted to the hematology-oncology unit at
Makassed General Hospital, Lebanon, from October 2009-January 2012.It corresponds
to epidemiological data on bacteremia episodes in febrile neutropenic cancer patients
including antimicrobial resistance and identification of risk factors associated with third
generation cephalosporin resistance (3GCR) and MDRO-associated bacteremia.
Results: Out of 75 bacteremias, 42.7% were gram-positive (GP), and 57.3% were
gram-negative (GN). GP bacteremias were mostly due to methicillin-resistant coagulase
negative staphylococci (28% of total bacteremias and 66% of GP bacteremias). Among
the GN bacteremias, Escherichia coli (22.7% of total, 39.5% of GN organisms) and
Klebsiella pneumoniae(13.3% of total, 23.3% of GN organisms) were the most important
causative agents. GN bacteremia due to 3GC sensitive (3GCS) bacteria represented
28% of total bacteremias, while 29% were due to 3GCR bacteria and 9% were due to
carbapenem-resistant organisms. There was a significant correlation between bacteremia
with MDRO and subsequent intubation, sepsis and mortality. Among potential risk factors,
only broad spectrum antibiotic intake >4 days before bacteremia was found to be
statistically significant for acquisition of 3GCR bacteria. Using carbapenems or piperacillin/
tazobactam>4 days before bacteremia was significantly associated with the emergence
of MDRO (p < 0.05).
Conclusion: Our findings have major implications for the management of febrile
neutropenia, especially in breakthrough bacteremia and fever when patients are already
on broadspectrum antibiotics. Emergence of resistance to 3GCs and, to a lesser extent,
to carbapenems in GN isolates has to be considered seriously in our local guidelines for
empiric treatment of febrile neutropenia, especially given that their occurrence was proven
to be associated with poorer outcomes.
Keywords: febrile neutropenia, bacteremia, 3GCR gram-negative bacteria, MDR gram-negative bacteria, Lebanon
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INTRODUCTION
The progress of anticancer therapy with aggressive supportive
care for patients with malignancies and patients undergoing
hematopoietic stem cell transplantation (HSCT) have recently
improved patient prognosis (Trecarichi and Tumbarello, 2014).
However, these advances, resulting in a prolonged and profound
level of immunosuppression, neutropenia in particular, along
with the extensive use of implantable medical devices, have also
increased the risk of severe infections (Trecarichi and Tumbarello,
2014). Different types of infections may occur in cancer patients,
but bloodstream infections (BSIs) are the most common severe
infectious complications; the reported prevalence of BSIs ranges
from 11 to 38%, and the crude mortality rate reaches up to 40%
(Wisplinghoff et al., 2003a,b; Tumbarello et al., 2012; Montassier
et al., 2013).
The type of microorganisms isolated on blood culture from
febrile neutropenic patients varies with time and place (Jones,
1999; Dettenkofer et al., 2003; Wisplinghoff et al., 2003b; Irfan
et al., 2008; Freifeld et al., 2011). Data from the Middle East and
North Africa (MENA) region is scarce.
At the beginning of the use of cytotoxic chemotherapy in
the 1960s and 1970s in cancer patients, gram-negative bacteria
(GNB) were the most common organisms causing bacteremia
in febrile neutropenic patients (Jones, 1999; Irfan et al., 2008);
however, at the turn of the century, the most common bacterial
pathogens isolated from blood cultures were coagulase-negative
staphylococci (Dettenkofer et al., 2003; Wisplinghoff et al., 2003b;
Freifeld et al., 2011).
However, in recent years several studies have demonstrated
a clear trend in the epidemiology of BSIs, showing a shift
of prevalence from gram-positive to gram-negative bacteria
(Wisplinghoff et al., 2003b; Pagano et al., 2012; Montassier et al.,
2013). There is an emergence of drug-resistant GNB such as mul-
tidrug resistant (MDR) Pseudomonas aeruginosa, Acinetobacter
baumannii, Stenotrophomonas maltophilia, extended-spectrum
beta-lactamase (ESBL)-producing GNB, and carbapenemase-
producing GNB (Zinner, 1999; Wisplinghoff et al., 2003b;
Ramphal, 2004; Freifeld et al., 2011; Pagano et al., 2012; Wu
et al., 2012; Montassier et al., 2013). The issue of antimicrobial
resistance has become a significant problem worldwide, where
treatment of infections due to MDR bacteria represents a clinical
challenge because the therapeutic options are often very limited.
Risk factors of bacteremia due to MDR GNB in febrile neu-
tropenic cancer patients vary depending on the type of organism,
duration of hospitalization, and antibiotic therapy (Gudiol and
Carratala, 2014).
So, the fact that the epidemiology of pathogens is dynamic
makes contemporary local data extremely important, and iden-
tification of pathogens locally recovered from blood cultures of
febrile neutropenic patients and the patterns of their antibi-
otic susceptibilities are essential in making therapeutic decisions
(Sigurdardottir et al., 2005).
The purpose of this study is to evaluate the epidemi-
ology of bacteremia occurring during neutropenia in adult
cancer chemotherapy patients in a university hospital in
Lebanon, with a special emphasis on the prevalence, sus-
ceptibility profile and risk factors associated with bacteremia
caused by third generation cephalosporin-resistant (3GCR) and
carbapenem-resistant bacteria.
MATERIALS AND METHODS
SETTING, PATIENTS AND STUDY DESIGN
This is retrospective study performed at Makassed General
Hospital, a 200-bed university hospital in Beirut, Lebanon. The
hospital’s Institutional Review Board approved the study, and an
informed consent was waived since it was observation. Medical
records of patients admitted between October 2009 and January
2012 were reviewed. Seventy-five episodes of bacteremia occur-
ring in 70 hospitalized neutropenic adult patients were recorded.
Adult cancer patients with fever and neutropenia, includ-
ing those undergoing Hematopoietic Stem Cell Transplantation
(HSCT), with positive blood cultures were selected. All posi-
tive results of blood cultures with the corresponding antibiogram
were checked and recorded from the Microbiology Laboratory
log books and computerized laboratory records. Information
regarding these episodes were collected and recorded in a specific
database from patients’ medical records.
Patient characteristics were identified, including age, gender,
type of cancer, risk level, recurrence of admissions, duration
of neutropenia prior to bacteremia, hospital stay prior to bac-
teremia, presence of a focus of infection, presence of a central
line or an implantable venous access, outcome, sepsis, intu-
bation, HSCT, antibiotic and antifungal intake in the hospital
setting. Univariate analysis of these characteristics was used to
identify risk factors for3GCR and multi-drug resistant (MDR)
organism-associated bacteremia.
DEFINITIONS AND INCLUSION CRITERIA
Patients were included if they met all three of the following
inclusion criteria:
(1) Fever, defined as a single oral temperature of 38.3◦C or an
oral temperature of 38◦C lasting 1 h or more.
(2) Neutropenia, defined as a neutrophil count of <500
cells/mm3, or a count of <1000 cells/mm3 with a docu-
mented decrease to <500 cells/mm3 within the following
48–72 h.
(3) Receipt of chemotherapy prior to the episode of
febrileneutropenia.
Patients who had fever and neutropenia as a result of their
underlying disease without having received chemotherapy were
excluded.
In Lebanon, anaerobic cultures are performed only in ref-
erence laboratories. Hospital-based laboratories perform only
aerobic cultures. According to hospital policy, one set of blood
cultures consists of two bottles of aerobic cultures taken from two
different draws at the same time, with no bottles for anaerobic
culture. Bacteremia is defined as isolation of the same bacterial
or pathogen from at least one set of blood cultures (2 bottles
taken at the same time). Bacteremia is considered polymicro-
bial if at least two organisms from the same blood culture on
two occasions are isolated or more than one organism each in
at least two separate blood cultureswithin 48 h (Reuben et al.,
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1989). Bacteremia occurring more than 14 days after a previous
episode and separated by repeatedly negative blood cultures was
considered a separate episode. Each separate hospital admission
for febrile neutropenia was defined as one episode. Subsequent
hospital admissions for febrile neutropenia in the same patient
were included as separate cases.
Bacteremia caused by a potential skin contaminant (such as
coagulase-negative staphylococci, Bacillus, or Corynebacterium
species) was considered significant only if it met the following
criteria:
(1) Growth of the same bacterial strainin two blood cultures
taken from two different sites at the same time.
(2) Growth of the same bacterial strain in one blood culture and
in one other sterile site (urine, cerebrospinal fluid, ascetic
fluid, pleural fluid, joint fluid).
(3) Growth of the same bacterial strain in one peripheral blood
culture and one blood culture taken from an intravenous
catheter where both cultures were taken at the same time.
Interpretive criteria (breakpoints) for susceptible, intermedi-
ate, and resistant bacterial isolates were those included in the
Clinical and Laboratory Standards Institute guidelines (Clinical
and Laboratory Standards Institute, 2010).
The 3GCR Enterobacteriaceae phenotypes included all isolates
not susceptible to one or more of five agents including aztreonam,
cefotaxime, ceftizoxime, ceftazidime, and ceftriaxone (Clinical
and Laboratory Standards Institute, 2010). These isolates were,
however, susceptible to imipenem.
Many different definitions for multidrug resistance are used in
the medical literature to characterize different patterns of resis-
tance in healthcare-associated, antimicrobial-resistant bacteria
(Magiorakos et al., 2012).However, generally speaking, MDR-
Gram negative bacteria are resistant to key antimicrobial agents
(Siegel et al., 2007; Hidron et al., 2008). Third and fourth
generation cephalosporins, along with fluoroquinolones, amino-
glycosides, and carbapenems, constitute the major therapeutic
options in treatment guidelines of febrile neutropenia in adult
cancer patients (Freifeld et al., 2011; Averbuch et al., 2013). In
this study, gram-negative bacteria were considered MDR when
resistant to third and fourth generation cephalosporins, fluoro-
quinolones, aminoglycosides and carbapenems, including S. mal-
tophilia, carbapenem-resistant P. aeruginosa and Acinetobacter
baumannii, or carbapenem-resistant 3GCR Enterobacteriaceae.
STATISTICAL ANALYSIS
Data were reported as the mean standard deviation (SD) or num-
ber of patients (percentage). T-tests (two-tailed), Fisher’s exact
tests and Chi-square tests were used to assess any significant dif-
ferencesamong the groups. P < 0.05 were considered statistically
significant.
RESULTS
During the study period, 75 episodes of bacteremia occurring
in 70 hospitalized neutropenic adult patients with hemato-
logical malignancies, including those undergoing HSCT, were
recorded. Epidemiological and clinical characteristics of the
patients, antibiotic treatment, and patient outcomes are shown
in Table 1.
Of the 75 bacteremias, 42.7% were due to gram-positive
organisms, and the remaining 57.3% were gram-negative.
Table 1 | Epidemiological and clinical characteristics of all episodes of
bacteremia.
Characteristic Total [n = 75(%)]
AGE (YEARS)
0–18 5 (6.67)
18–65 62 (82.67)
>65 8 (10.67)
GENDER
Male 36 (48)
Female 39 (52)
TUMOR TYPE
Leukemia 56 (74.67)
Lymphoma 15 (20)
Solid 4 (5.33)
MASCC score
>21 5 (6.67)
<21 70 (93.33)
NEUTROPENIA DURATION PRIOR TO BACTEREMIA
<7 days 26 (34.67)
>7 days 26 (34.67)
Unknown 23 (30.67)
HOSPITAL STAY PRIOR TO BACTEREMIA
<2 days 21 (28)
Between 2 and 7 days 4 (5.33)
>7 days 48 (64)
Unknown 2 (2.67)
RECURRENT ADMISSION
Yes 67 (89.33)
No 8 (10.67)
FOCUS OF INFECTION
No/Unknown 17 (22.67)
Pneumonia 3 (4)
Gastroenteritis 13 (17.33)
Urinary tract infection 7 (9.33)
Skin and soft tissue infection 3 (4)
Central line associated 30 (40)
Portal catheter associated 2 (2.67)
PLACEMENT OF CENTRAL VENOUS CATHETER
Yes 52 (69.33)
<10 days 18 (24)
>10 days 34 (45.33)
No 23 (30.67)
OUTCOME
Death 7 (9.33)
Recovery 68 (90.67)
Sepsis 8 (10.67)
Intubation 7 (9.33)
Hematopoietic stem cell transplantation 41 (54.67)
N.B. MASCC, Multinational Association of Supportive Care in Cancer.
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Gram-positive bacteremias were mostly due to methicillin-
resistant coagulase negative staphylococci, which represented
66% of gram-positive bacteremias and 28% of total bacteremias.
No methicillin-resistant Staphylococcus aureus-related bacteremia
was detected and only one episode of methicillin-sensitive
Staphylococcus aureus-related bacteremia was observed. (Refer to
Tables 2, 3).
Among the gram-negative bacteremias, Escherichia coli (22.7%
of total, 39.5% of gram-negative) and Klebsiella pneumonia
(13.3% of total, 23.3% of gram-negative)were themost important
causative agents. Out of the 17 bacteremias caused by E. coli, eight
were due to 3GCR resistant strains (10.7% of total bacteremias
and 47% of E. coli strains). From those caused by K. pneumoniae
(10 bacteremias), five cases were due to 3GCR strains (6.7% of
total bacteremia and 50% of K. pneumoniae). In general, 28% of
the total bacteremias were due to 3GC sensitive gram-negative
bacteria and 29.3% of the total bacteremias were caused by
3GC resistant gram-negative bacteria. Concerning carbapenem
susceptibility in the 3GC resistant category, seven cases were
carbapenem-resistant, representing 9.3% of total bacteremias.
(Refer to Tables 2, 4).
Results of the univariate analysis of factors potentially asso-
ciated with 3GCR bacteremia, including baseline and demo-
graphic characteristics, major disease and risk, hospitalization
Table 2 | Causative organisms of all episodes of bacteremia.
Causative organisms Number of episodes
[n = 75(%)]
gram-positive Bacteria 32 (42.67)
Staphylococcus aureus 1 (1.33)
Coagulase-negative staphylococci (CNS) 28 (37.33)
Methicillin resistant CNS 21 (28)
Streptococcus pneumoniae 1 (1.33)
Enterococcus faecium 1 (1.33)
Aerococcus viridans 1 (1.33)
gram-negative Bacteria (GNB) 43 (57.33)
Escherichia coli 17 (22.67)
3GCR -Escherichia coli 8 (10.67)
Pseudomonas aeruginosa 3 (4)
Pseudomonas putida 1 (1.33)
Pseudomonas stutzeri 1 (1.33)
Klebsiella pneumoniae 10 (13.33)
3GCR- Klebsiella pneumoniae 5 (6.67)
Klebsiella oxytoca 1 (1.33)
Proteus mirabilis 3 (4)
Enterobacter cloacae 2 (2.67)
Acinetobacter baumannii 2 (2.67)
Stenotrophomonas maltophilia 2 (2.67)
Salmonella species 1 (1.33)
3GC sensitive GNB 21 (28)
3GCR GNB 22 (29.33)
3GCR carbapenem-sensitive GNB 15 (20)
3GCR carbapenem-resistant GNB 7 (9.33)
N.B. 3GCR, third generation cephalosporin-resistant.
prior to bacteremia, recurrent admissions, neutropenia prior to
bacteremia, presence of CVC, and focus of infection, did not show
any statistical significance, suggesting that the former factors were
not risk factors. However, history and duration of antibiotic
intake before the episode of bacteremia was majorly implicated in
the occurrence of 3GCR bacteremia. The type of broad spectrum
antibiotic use did not affect the results; butduration of intake did
affect results. The use of carbapenems, piperacillin/tazobactam,
or 3rd or 4th GC ± aminoglycosides for more than 4 days prior
to the bacteremic episode was significantly associated with 3GCR
bacteremia compared with all other types of bacteremias. (P <
0.01) A worse outcome, defined by need for intubation and the
occurrence of sepsis in bacteremic patients, was also statistically
significant in the 3GCR group compared with the other groups.
(P < 0.03) (Refer to Tables 5, 6).
Similarly, infection with an MDR strain was associated with
significantly higher rates of subsequent intubation, sepsis, and
mortality. (P < 0.03)The history and duration of antibiotic
intake before the episode of bacteremia was significantly asso-
ciated with the occurrence of MDR bacteremia as well. The
use of cephalosporins ± aminoglycosides was not significantly
associated with MDR bacteremia, while the use of carbapen-
ems or piperacillin/tazobactam for more than 4 days prior to
MDR-bacteremia was significantly associated with its occurrence.
(P < 0.04) (Refer to Tables 5, 6).
DISCUSSION
Data from Lebanon in neutropenic patients is scarce, and the
available literature reveals the dynamic nature of the etiology
of bacteremias with time. Previous studies from Lebanon have
shown gram-negative organisms to be the predominant agents in
febrile neutropenic patients (Hamzeh et al., 2000; Kanafani et al.,
2007). In addition to the subdivision between gram-positive and
gram-negative organisms, we investigated antibiotic susceptibility
patterns and the risk factors associated with bacteremia caused by
antibiotic-resistant gram-negative organisms.
In this study, the distribution of the 75 cases was almost equal
between gram-positive and gram-negative organisms (42.7 vs.
57.3%). Yet, a study by Kanafani et al. (2007) in 2007 from
Lebanon showed gram-negative predominance in febrile neu-
tropenia bacteremic episodes. Gram-negative organisms were
responsible for 78.8% of bloodstream infections compared with
33.3% gram-positive organisms (Kanafani et al., 2007).
In fact, the shift from a preponderance of gram-negative bacte-
ria causing bloodstream infections in febrile neutropenic patients
to gram-positive bacteria has been observed worldwide. The
widespread use of indwelling catheters, early-generation fluoro-
quinolone prophylaxis, and broad spectrum empirical anti-gram-
negative antibacterial therapy led to an increase in the incidence
of gram-positive pathogens in the 1980s and 1990s (Zinner, 1999;
Ramphal, 2004; Freifeld et al., 2011). Thereafter, the most com-
mon bacterial etiologic agent isolated from blood cultures in
most centers was reported to be coagulase-negative staphylococci
(Dettenkofer et al., 2003; Wisplinghoff et al., 2003b; Freifeld et al.,
2011). In our study, coagulase-negative staphylococci were the
most common among gram-positive organisms (37.3% of total
cases, 87.5% of gram-positive cases), where methicillin-resistant
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Table 3 | Antibiotic susceptibility profile of isolated gram-positive bacteria.
Antibiotic No of susceptible gram-positive isolates (%)
CNS S. aureus S. pneumoniae E. faecium A. viridans Total
[n = 28(%)] [n = 1(%)] [n = 1(%)] [n = 1(%)] [n = 1(%)] [n = 32(%)]
Oxacillin 7 (25) 1 (100) 1 (100) 0 (0) 0 (0) 9 (28.1)
Ampicillin – 1 (100) 1 (100) 0 (0) 0 (0) 10 (31.3)
Rifampin 24 (85.7) 1 (100) 1 (100) 0 (0) 0 (0) 26 (81.3)
Clindamycin 16 (57.1) 1 (100) 1 (100) 0 (0) 1 (100) 19 (59.4)
Teicoplanin 28 (100) 1 (100) 1 (100) 1 (100) 1 (100) 32 (100)
Vancomycin 28 (100) 1 (100) 1 (100) 1 (100) 1 (100) 32 (100)
N.B. A.viridans, Aerococcus viridans; CNS, Coagulase Negative Staphylococci; E. faecium, Enterococcus faecium; S. aureus, Staphylococcus aureus; S. pneumoniae,
Streptococcus pneumonia.
Table 4 | Antibiotic susceptibility profile of isolated gram-negative bacteria.
No. of susceptible gram-negative isolates (%)
Antibiotic E. coli Klebsiella Pseudomonas P.mirabilis Enterobacter S. maltophilia A. baumannii Salmonella Total
[n = 17(%)] spp. spp. [n = 3(%)] spp. [n = 2(%)] [n = 2(%)] spp. [n = 43(%)]
[n = 11(%)] [n = 5(%)] [n = 2(%)] [n = 1(%)]
Amox/Clav 5 (29.4) 5 (45.5) 0 (0) 3 (100) 0 (0) 0 (0) 0 (0) 1 (100) 11 (25.6)
Amikacin 15 (88.2) 10 (90.9) 5 (100) 3 (100) 2 (100) 0 (0) 1 (50) 1 (100) 37 (86)
Cefepime 5 (29.4) 6 (54.5) 3 (60) 3 (100) 1 (50) 0 (0) 0 (0) 1 (100) 19 (44.2)
Ceftazidime 8 (57.1) 5 (45.5) 4 (80) 3 (100) 0 (0) 1 (50) 1 (50) 1 (100) 23 (53.5)
Ceftriaxone 8 (57.1) 6 (54.5) 2 (40) 3 (100) 0 (0) 0 (0) 0 (0) 1 (100) 19 (44.2)
Imipenem 14 (82.4) 11 (100) 4 (80) 3 (100) 2 (100) 0 (0) 1 (50) 1 (100) 36 (83.7)
Pip/Tazo 13 (76.5) 7 (63.6) 5 (100) 3 (100) 0 (0) 0 (0) 1 (50) 1 (100) 30 (69.8)
Tigecycline 17 (100) 10 (90.9) 1 (20) 3 (100) 2 (100) 2 (100) 2 (100) 1 (100) 40 (93)
Colistin 17 (100) 11 (100) 4 (80) 3 (100) 2 (100) 0 (0) 2 (100) 1 (100) 40 (93)
Quinolones 7 (41.2) 7 (63.6) 4 (80) 1 (33.3) 0 (0) 2 (100) 1 (50) 0 (0) 22 (51.2)
N.B. A.baumannii, Acinetobacter baumannii; Amox/Clav, Amoxicillin/Clavulanate; E. coli, Escherichia coli; Pip/Tazo, Piperacillin/Tazobactam; P.mirabilis, Proteus
mirabilis; S. maltophilia, Stenotrophomonas maltophilia; spp, species.
coagulase-negative staphylococciisolatesrepresented 28% of the
total cases and 65.6% of gram-positive cases.
Our results showed that E. coli and K. pneumoniae were the
most prevalent gram-negative organisms, representing 22.7 and
13.3%, respectively, of total cases. A systematic literature review
conducted by Trecarichi and Tumbarello (2014) from January
2007 to August 2013 examined the recent trends in epidemiology
and antimicrobial resistance in gram-negative bacteria recovered
from cancer patients, with a particular emphasis on the impact of
antimicrobial resistance on the clinical outcome of severe infec-
tions caused by such microorganisms. The gram-negative bacte-
rial species most frequently isolated were E. coli, whose frequency
ranged from 10.1 to 53.6% (mean 32.1%), and K. pneumoniae,
which was isolated with a frequency ranging from 4.1 to 44.6%
(mean 19.5%) (Trecarichi and Tumbarello, 2014).
In our study, 3GCR strains of E. coli and K. pneumoniae
caused 10.7 and 6.7% of total bacteremias, respectively. 3GCR-
Enterobacteriaceae colonization or infection of patients with
febrile neutropenia has been reported with increased frequency
during the last decade. Bloodstream infections due to 3GCR
E. coli isolates have been reported with a frequency ranging
from 12 to 75% (mean 35%) in cancer patients. 3GCR K. pneu-
moniae isolates causing BSIs in neutropenic patients have been
reported with a frequency ranging from 3 to 66.6% (mean 37.8%)
(Trecarichi and Tumbarello, 2014).
We found that 9.3% of episodes of bacteremia in cancer
patients were caused by MDR gram-negative bacteria. This
finding is in line with recent studies, which report an increase in
antibiotic resistance among gram-negative bacteria in immuno-
compromised hosts. One study performed in Italy by Gudiol et al.
(2011) reported an incidence of 13.7% of MDR gram-negative
associated bacteremia, andin another study performed in Pakistan
by Irfan et al. (2008), the emergence of carbapenem resistance
was reported in Pseudomonas species (20.7% of the isolates)
and in Acinetobacter species (65.4% of the isolates). In another
study by Trecarichi et al. (2011) from Italy, among 38 patients
diagnosed with P. aeruginosa bacteremia, 27 were MDR species
(71.1%). The percentages of in vitro resistance to major antimi-
crobial classes were the following: carbapenems (imipenem
and meropenem) 60%, antipseudomonal cephalosporins
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Table 5 | Baseline and demographic characteristics, clinical features, and outcome of patients with 3GCR-bacteremia compared with
non-3GCR-bacteremia and MDR-bacteremia compared with non-MDR-bacteremia.
Characteristic 3GCR-Bacteremia Non-3GCR-Bacteremia P-value MDR Bacteremia Non-MDR Bacteremia P-value
[n = 22(%)] [n = 53(%)] [n = 7(%)] [n = 68(%)]
AGE (YEARS)
0–18 1 (4.5) 4 (7.5) 0 (0) 5 (7.4)
18–65 19 (86.4) 43 (81.1) 6 (85.7) 56 (82.4)
>65 2 (9.1) 6 (11.3) 0.846 1 (14.3) 7 (10.3) 0.734
GENDER
Male 9 (40.9) 27 (50.9) 3 (42.9) 33 (48.5)
Female 13 (59.1) 26 (49.1) 0.428 4 (57.1) 35 (51.5) 0.775
TUMOR TYPE
Leukemia 17 (77.3) 39 (73.6) 6 (85.7) 50 (73.5)
Lymphoma 4 (18.2) 11 (20.8) 0 (0) 15 (22.1)
Solid 1 (4.5) 3 (5.7) 0.944 1 (14.3) 3 (4.4) 0.243
MASCC SCORE
>21 0 (0) 5 (9.4) 0 (0) 5 (7.4)
<21 22 (100) 48 (90.6) 0.136 7 (100) 63 (92.6) 0.458
NEUTROPENIA DURATION PRIOR TO BACTEREMIA
<7 days 8 (36.4) 15 (28.3) 3 (42.9) 20 (29.4)
>7 days 7 (31.8) 19 (35.8) 1 (14.3) 25 (36.8)
Unknown 7 (31.8) 19 (35.8) 0.789 3 (42.9) 23 (33.8) 0.485
HOSPITAL STAY PRIOR TO BACTEREMIA
<2 days 7 (31.8) 14 (26.4) 2 (28.6) 19 (27.9)
Between 2 and 7 days 2 (9.1) 2 (3.8) 1 (14.3) 3 (4.4)
>7 days 13 (59.1) 35 (66) 4 (57.1) 44 (64.7)
Unknown 0 (0) 2 (3.8) 0.586 0 (0) 2 (2.9) 0.700
RECURRENT ADMISSION
Yes 2 (9.1) 6 (11.3) 0 (0) 8 (11.8)
No 20 (90.9) 47 (88.7) 0.776 7 (100) 60 (88.2) 0.337
FOCUS OF INFECTION
No/Unknown 3 (13.6) 14 (26.4) 1 (14.3) 16 (23.5)
Pneumonia 1 (4.5) 2 (3.8) 1 (14.3) 2 (2.9)
Gastroenteritis 0 (0) 3 (5.7) 0 (0) 3 (4.4)
UTI 6 (27.3) 7 (13.2) 2 (28.6) 11 (16.2)
SStI 8 (36.4) 22 (41.5) 2 (28.6) 28 (41.2)
Central line associated 1 (4.5) 1 (1.9) 0 (0) 2 (2.9)
Portal catheter associated 3 (13.6) 4 (7.5) 0.507 1 (14.3) 6 (8.8) 0.702
PLACEMENT OF CVC
Yes 7 (31.8) 16 (30.2) 2 (28.6) 21 (30.9)
<10 days 6 (27.3) 12 (22.6) 3 (42.9) 15 (22.1)
>10 days 9 (40.9) 25 (47.2) 2 (28.6) 32 (47.1)
No 7 (31.8) 16 (30.2) 0.866 2 (28.6) 21 (30.9) 0.442
OUTCOME
Death 5 (22.7) 2 (3.8) 4 (57.1) 3 (4.4)
Recovery 17 (77.3) 51 (96.2) 0.010 3 (42.9) 65 (95.6) <0.0001
Sepsis 5 (22.7) 3 (5.7) 0.029 4 (57.1) 4 (5.9) <0.0001
Intubation 5 (22.7) 2 (3.8) 0.010 4 (57.1) 3 (4.4) <0.0001
HSCT 13 (59.1) 29 (54.7) 0.728 4 (57.1) 38 (55.9) 0.949
N.B. MASCC, Multinational Association of Supportive Care in Cancer, UTI, Urinary tract infection; SStI, Skin and soft tissue Infection; CVC, Central Venous Catheter;
HSCT, Hematopoietic stem cell transplantation.
(ceftazidime and cefepime) 42%, and piperacillin 24%
(Trecarichi et al., 2011).
The emergence of 3GCR Enterobacteriaceae and MDR gram-
negative organisms causing bacteremia in cancer patients is very
critical in terms of empiric therapy for febrile neutropenia.
Third and fourth generation cephalosporins remain the first line
option for primary therapy in febrile neutropenia (Freifeld et al.,
2011; Averbuch et al., 2013). In this group of patients, appro-
priate initial empirical antibiotic therapy is essential, (Gudiol
and Carratala, 2014) and empiric antibiotic therapy in febrile
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Table 6 | Antimicrobial history and duration prior to bacteremia in all cases, in patients with 3GCR- bacteremia compared with
non-3GCR-bacteremia and in MDR-bacteremiacompared with non-MDR-bacteremia.
Antimicrobial duration
before bacteremia
Total 3GCR- Non-3GCR- P-value MDR- Non-MDR- P-value
n = 75 (%) Bacteremia Bacteremia Bacteremia Bacteremia
[n = 22(%)] [n = 53(%)] [n = 7(%)] [n = 68(%)]
Carbapenem (Group1) <4
days
8 (10.67) 1 (4.5) 7 (13.2) 0.269 1 (14.3) 7 (10.3) 0.745
Carbapenem>4 days 14 (18.67) 8 (36.4) 6 (11.3) 0.011 4 (57.1) 10 (14.7) 0.006
No Carbapenem 55 (73.33) 1 (4.5) 4 (7.5) 0.635 1 (14.3) 4 (5.9) 0.396
PIP/TAZ (Group2) <4 days 5 (6.67) 5 (22.7) 2 (3.8) 0.010 2 (28.6) 5 (7.4) 0.066
PIP/TAZ >4 days 7 (9.33) 3 (13.6) 12 (22.6) 0.375 3 (42.9) 12 (17.6) 0.112
No PIP/TAZ 65 (86.67) 6 (27.3) 5 (9.4) 0.047 2 (28.6) 9 (13.2) 0.275
3rd or 4th GC ± Amikacin
(Group3) <4 days
15 (20) 3 (13.6) 12 (22.6) 0.375 3 (42.9) 12(17.6) 0.112
3rd or 4th GC ± Amikacin>4
days
11 (14.67) 8 (36.4) 6 (11.3) 0.011 3 (42.9) 11 (16.2) 0.085
No 3rd or 4th GC ± Amikacin 51 (68) 2 (9.1) 11 (20.8) 0.224 2 (28.6) 11 (16.2) 0.409
Group 1 or 2 or 3 <4 days 15 (20) 7 (31.8) 5 (9.4) 0.016 3 (42.9) 9 (13.2) 0.042
Group 1 or 2 or 3 >4 days 14 (18.67) 2 (9.1) 5 (9.4) 0.963 2 (28.6) 5 (7.4) 0.066
No group 2 or 3 or 4 49 (65.33) 4 (18.2) 5 (9.4) 0.288 2 (28.6) 7 (10.3) 0.156
Carbapenem or PIP/TAZ <4
days
13 (17.33) 1 (4.5) 7 (13.2) 0.269 1 (14.3) 7 (10.3) 0.745
Carbapenem or PIP/TAZ >4
days
12 (16) 8 (36.4) 6 (11.3) 0.011 4 (57.1) 10 (14.7) 0.006
No Carbapenem or PIP/TAZ 52 (69.33) 1 (4.5) 4 (7.5) 0.635 1 (14.3) 4 (5.9) 0.396
Antifungal other than
Fluconazole <4 days
7 (9.33) 5 (22.7) 2 (3.8) 0.010 2 (28.6) 5 (7.4) 0.066
Antifungal other than
Fluconazole >4 days
9 (12) 3 (13.6) 12 (22.6) 0.375 3 (42.9) 12 (17.6) 0.112
No Antifungal other than
Fluconazole
62 (82.67) 6 (27.3) 5 (9.4) 0.047 2 (28.6) 9 (13.2) 0.275
N.B. PIP/TAZ, Piperacillin/Tazobactam; 3rd or 4th GC, Third or Fourth Generation Cephalosporin.
neutropenic patients has reduced mortality rates from approxi-
mately 21% (Viscoli et al., 2005) to 2–10%, (Vidal et al., 2004;
Toussaint et al., 2006) depending upon the underlying diagnosis,
degree of cancer control, duration of severe neutropenia and type
of infection. Inappropriate empiric therapy is defined, in con-
text, as not including at least one antibiotic active in vitro against
the infecting microorganism(s) (Freifeld et al., 2011; Averbuch
et al., 2013), and the emergence of 3GCR and MDR organisms in
febrile neutropenia renders 3rd or 4th GCs inappropriate choices
in certain situations.
Our results showed that the use of broad spectrum antibiotics,
including carbapenems, piperacillin/tazobactam, and 3rd or 4th
GC ± aminoglycosides, for more than 4 days prior to bacteremia
was significantly associated with 3GCR bacteremia. (P < 0.01)
However, in the case of carbapenem-resistant 3GCR bacteremia
(MDR), the use of carbapenems or piperacillin/tazobactam,
but not cephalosporins, for more than 4 days prior to MDR-
bacteremia was significantly associated with its occurrence. (P <
0.04) (Refer to Table 6) Previous antibiotic therapy has been rec-
ognized as a major risk factor for the development of bacterial
resistance. In prospective study involving13 Brazilian HSCT cen-
ters (Oliveira et al., 2007), 22% of 91 episodes of bacteremia
were MDR-gram-negative in origin. Previous exposure to third
generation cephalosporins either as prophylaxis or empirical ther-
apy and belonging to one of the HSCT centers were associated
with an increased risk for ESBL-producing Enterobacteriaceae
(Oliveira et al., 2007).Another retrospective case-control study
involving HSCT recipients (Garnica et al., 2009) showed by
univariate analysis that previous use of a third or fourth-
generation cephalosporin (P = 0.005 and 0.02, respectively) and
duration of antibiotic use (P < 0.001) were among the factors
associated with bacteremia due to MDR-gram-negative isolates
including K. pneumonia and P. aeruginosa. In another study
performed in the United States by Rangaraj et al. (2010), the
use of multiple broad spectrum antibiotics compared with no
antimicrobial agents was significantly associated with isolation
of MDR P. aeruginosa (8.2 vs. 0.7%, p < 0.005).This finding
is consistent with a more recent study in 2013 by Satlin et al.
(2013), where exposure to any broadspectrum antibacterial agent
may be sufficient to increase the risk of carbapenem-resistant
Enterobacteriaceae acquisition and cause bloodstream infections
in patients with hematologic malignancies.
Our results showed that patient outcome was influenced sig-
nificantly by antimicrobial resistance, and the risk ofsubsequent
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intubation, sepsis and mortality were high in the 3GC-resistant
bacteremia group and in the MDR-bacteremia group com-
pared with patients having other bacteremias(P < 0.03).(Refer to
Table 5) Other studies indicated that a dramatic increase in the
detection rate of MDR gram-negative bacteremia compared with
previous periods was associated with increased morbidity, mor-
tality, and cost, especially in patients with hematological diseases
(Lodise et al., 2007). Moreover, mortality was independently asso-
ciated with inadequate initial antimicrobial treatment in the case
of antibiotic-resistant bacteremia (Giske et al., 2008). Thus, local
monitoring of bacterial isolates is recommended to adapt initial
empiric antibiotic therapy based on the local prevalence of MDR
strains (Caselli et al., 2010).
Our study has at least two major limitations. The first is that
the samples were collected from a single medical center; there-
fore, results could not be generalized to other medical centers in
Lebanon because the microbial ecology differs from one center to
another. The second limitation is that the small sample size did
not allow us to perform a multivariate analysis and limited our
statistical analysis to a univariate model.
CONCLUSION
In conclusion, our data showed equal occurrence of gram-
negative and gram-positive organisms causing bacteremia in
febrile neutropenic cancer patients in our center. We found
that bacteremia caused by gram-negative antimicrobial resistant
strains is common among cancer patients, especially in those
exposed to antibiotic pressure. Emergence of resistance to third
and fourth generation cephalosporins and, to a lesser extent,
to carbapenems, in gram-negative isolates has to be considered
seriously in our local guidelines for empiric treatment of febrile
neutropenia, especially given that their occurrence was associated
with poorer clinical outcomes.
The empiric use of broad spectrum antibiotics in febrile neu-
tropenia is very critical. On the one hand, it is crucial to decrease
mortality during the febrile episode; on the other hand, it is a risk
factor for emergence bacteremia with resistant organisms. In our
therapeutic guidelines for the management of febrile neutrope-
nia, we should include coverage forMDR bacteria in patients who
have persistent or relapsing fever after 4 days of initial empiric
therapy.
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